Clinical trials: Stage 1 Hypertension
Essential Hypertension
Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension
In patients naive to treatment or after a 2-week washout period for patients whose treatment was ineffective, the use of olmesartan was assessed in a 4-phase treatment scheme: monotherapy, addition of hydrochlorothiazide (2…
- Trial name
- Benibest (NCT00890591)
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary
- Volunteers
- 144 people
- Sponsor
- Daiichi Sankyo
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure.
- Trial name
- NCT00403481
- Testing
- olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
- Where
- 27 sites in United States
- Volunteers
- 192 people
- Sponsor
- Daiichi Sankyo
Hypertension
A Dose Finding Study Of PF-00489791 In Patients With Mild To Moderate High Blood Pressure
The purpose of this study is to evaluate the safety and blood pressure lowering effect of different doses of PF-00489791 in patients with mild to moderate high blood pressure
- Trial name
- NCT00422461
- Testing
- PF-00489791
- Where
- 20 sites in United States
- Volunteers
- 135 people
- Sponsor
- Pfizer
Pulmonary Hypertension
Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
mTOR activation has been shown to be relevant in the development and progression of pulmonary hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension in animal models.
- Trial name
- NCT02587325
- Testing
- nab-sirolimus
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Aadi Bioscience, Inc.
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Elderly Patients With Hypertension
This 14 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients 65 years of age or older with high blood pressure.
- Trial name
- NCT00412932
- Testing
- Olmesartan medoxomil, Olmesartan medoxomil/hydrochlorothiazide
- Where
- 29 sites in United States
- Volunteers
- 178 people
- Sponsor
- Daiichi Sankyo
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH Subjects
Study ROR-PH-302, ADVANCE CAPACITY, was designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after…
- Trial name
- CAPACITY (NCT04084678)
- Testing
- Ralinepag
- Where
- 33 sites in United States, Argentina and 10 more
- Volunteers
- 10 people
- Sponsor
- United Therapeutics
Mild to Moderate Hypertension
A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.
- Trial name
- NCT06423352
- Testing
- Zilebesiran
- Where
- 3 sites in Japan
- Volunteers
- 36 people
- Sponsor
- Alnylam Pharmaceuticals
Hypertension
Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years)
The purpose of this study is to assess the efficacy, safety, and tolerability of 8 weeks of therapy with nebivolol in comparison to placebo in younger patients 18 - 54 years of age with stage 1 or stage 2 essential hypertension.
- Trial name
- NCT01415531
- Testing
- Nebivolol
- Where
- 75 sites in United States
- Volunteers
- 641 people
- Sponsor
- Forest Laboratories
Hypertension
A Trial to Evaluate the Safety and Efficacy of PS433540 to Treat Hypertension
The purpose of the study is to see if PS433540 lowers blood pressure better than placebo and to see how safe PS433540 is compared to placebo.
- Trial name
- NCT00522925
- Testing
- PS433540
- Where
- 15 sites in United States
- Volunteers
- 280 people
- Sponsor
- Ligand Pharmaceuticals
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the…
- Trial name
- A DUE (NCT03904693)
- Testing
- FDC macitentan/tadalafil, Macitentan 10 mg, Tadalafil 40 mg
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 187 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
Sitaxsentan has a low drug-drug interaction potential and it did not have a clinically relevant effect on pharmacokinetics of sildenafil (a CYP3A sensitive substrate and PDE5 inhibitor).
- Trial name
- NCT01244620
- Testing
- sitaxentan, tadalafil, sitaxsentan
- Where
- Singapore
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hypertension, Blood Pressure
HIRREM for Stage 1 Primary Hypertension
The purpose of this study is to determine that effects of an intervention called High-resolution, relational, resonance-based, electroencephalic mirroring (HIRREM), on Stage 1 Primary Hypertension (systolic BP 130-139, and/or…
- Conditions
- Hypertension, Blood Pressure, Cardiovascular Diseases, Cardiovascular Risk Factor
- Trial name
- HIRREM (NCT03479697)
- Testing
- HIRREM, Continued Current Care
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Wake Forest University Health Sciences
Hypertension
A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients
This study will evaluate the efficacy and safety of nebivolol monotherapy in Hispanic patients with stage 1 or stage 2 hypertension
- Trial name
- NCT00770861
- Testing
- Nebivolol
- Where
- 32 sites in United States, Puerto Rico
- Volunteers
- 277 people
- Sponsor
- Forest Laboratories
Essential Hypertension
Safety Study of RMJH-111b to Treat Essential Hypertension
The purpose of this study was to evaluate the safety of RMJH-111b, including how well it is tolerated, and the effect of RMJH-111b on blood pressure in subjects with hypertension.
- Trial name
- NCT02822222
- Testing
- Magnesium citrate, tribasic anhydrous soft gelatin capsule
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- RMJ Holdings, LLC
Hypertension
One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
This purpose of this study is to evaluate the long-term safety and tolerability of azilsartan medoxomil in individuals with essential hypertension.
- Trial name
- NCT00695955
- Testing
- Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
- Where
- 41 sites in United States, Chile and 1 more
- Volunteers
- 669 people
- Sponsor
- Takeda
Pre-Eclampsia, Stage 1 Hypertension
Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)
To determine if low dose aspirin reduces the incidence of hypertensive disorders of pregnancy (gestational hypertension, preeclampsia, eclampsia, and HELLP syndrome) in pregnant women with stage 1 hypertension and elevated blood…
- Conditions
- Pre-Eclampsia, Stage 1 Hypertension, Elevated Blood Pressure
- Trial name
- NCT04402385
- Testing
- Aspirin 81 mg
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Yale University
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Hypertension
A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension
This 16 week study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with moderate to severe high blood pressure in comparison to placebo.
- Trial name
- NCT00430638
- Testing
- olmesartan medoxomil + hydrochlorothiazide, if necessary
- Where
- 29 sites in United States
- Volunteers
- 278 people
- Sponsor
- Daiichi Sankyo
Pulmonary Artery Hypertension
GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
The primary objective for this trial is to determine the effect of GB002 (seralutinib) on improving pulmonary hemodynamics in subjects with World Health Organization (WHO) Group 1 PAH who are Functional Class (FC) II and III.
- Trial name
- NCT04456998
- Testing
- GB002 (seralutinib), Generic Dry Powder Inhaler
- Where
- 63 sites in United States, Australia and 9 more
- Volunteers
- 86 people
- Sponsor
- GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Hypertension
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
- Trial name
- NCT00281580
- Testing
- Amlodipine 5 mg, Telmisartan 20 mg, Telmisartan 40 mg
- Where
- 136 sites in United States, Argentina and 3 more
- Volunteers
- 1,461 people
- Sponsor
- Boehringer Ingelheim